Changes in Hong Kong stocks | Xintai Healthcare (02291) rose more than 18% in the morning memoSorb ASD/VSD blocker was approved for listing in Saudi Arabia

The Zhitong Finance App learned that Xintai Healthcare (02291) rose by more than 18% in the morning. As of press release, it had risen 16.49% to HK$13.07, with a turnover of HK$5.93,500.

According to news, in July, the memoSorb® biodegradable atrial septal defect (ASD) occluder and fully degradable chamber septal defect (VSD) occluder independently developed by Xintai Medical were approved for medical device marketing in Saudi Arabia. As early as April, biodegradable ovalvular hole unclosed (PFO) blockers and transcatheter implantable aortic valve systems (TAVR) were the first to be approved for marketing in Saudi Arabia.

According to reports, Saudi Arabia, as one of the largest medical markets in the Middle East, is known for its high standards and strict requirements, and has been widely recognized by the Gulf Cooperation Council (GCC) countries and neighboring markets. This approval means that Xintai Medical's structural heart disease solution system centered on the memosorb® PFO/ASD/VSD occluder matrix+Sciencrow® TAVR system has been fully implemented in the Middle East market and received regulatory approval from overseas authorities, laying a solid foundation for subsequent clinical application in the Middle East region and serving more cardiovascular disease patients around the world.